Difference between revisions of "Glycoprotein non-metastatic B"
Jump to navigation
Jump to search
| (One intermediate revision by the same user not shown) | |||
| Line 11: | Line 11: | ||
*[[Renal cell carcinoma with fibromyomatous stroma]]. | *[[Renal cell carcinoma with fibromyomatous stroma]]. | ||
==Negative | Others: | ||
*[[Leiomyosarcoma]].{{fact}} | |||
==Negative== | |||
*[[Clear cell renal cell carcinoma]]. | *[[Clear cell renal cell carcinoma]]. | ||
*[[Papillary renal cell carcinoma]]. | *[[Papillary renal cell carcinoma]]. | ||
Latest revision as of 13:33, 26 March 2024
Glycoprotein non-metastatic B, abbreviated GPNMB, is an immunostain.
It is typically positive in TSC1/TSC2/MTOR mutated renal cell carcinomas.[1]
Positive
- Angiomyolipoma.
- TFE3-rearranged renal cell carcinoma.
- TFEB-rearranged renal cell carcinoma.
- Low-grade oncocytic tumour (LOT).
- PEComa.
- Renal cell carcinoma with fibromyomatous stroma.
Others:
Negative
- Clear cell renal cell carcinoma.
- Papillary renal cell carcinoma.
- Chromophobe renal cell carcinoma.
- Clear cell papillary renal cell tumour.
References
- ↑ Li H, Argani P, Halper-Stromberg E, Lotan TL, Merino MJ, Reuter VE, Matoso A (November 2023). "Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others". Am J Surg Pathol 47 (11): 1267–1273. doi:10.1097/PAS.0000000000002117. PMID 37661807.